HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

proaerolysin

a bacterial toxin that forms pores in host cells by oligomerization; protein precursor of aerolysin; amino acid sequence given in first source

Also Known As:

pro-aerolysin

Networked: 8 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Biological Factors: 2472
- Biological Toxins: 20
  - Bacterial Toxins: 814
    - proaerolysin: 8
Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843
  - Membrane Proteins: 10078
    - Pore Forming Cytotoxic Proteins
      - proaerolysin: 8

Experts

1.	Denmeade, Samuel R: 2 articles (04/2013 - 08/2007)
2.	Merchant, Rosemina: 2 articles (04/2013 - 08/2007)
3.	Brodsky, Robert A: 2 articles (08/2012 - 04/2009)
4.	Hu, Rong: 2 articles (08/2012 - 04/2009)
5.	Mukhina, Galina L: 2 articles (08/2012 - 04/2009)
6.	Ding, Jing: 1 article (01/2020)
7.	Gu, Haihui: 1 article (01/2020)
8.	Guo, Mengqiao: 1 article (01/2020)
9.	Tang, Gusheng: 1 article (01/2020)
10.	Wang, Ziwei: 1 article (01/2020)

Related Diseases

1.	Paroxysmal Hemoglobinuria (Paroxysmal Nocturnal Hemoglobinuria) 01/01/2020 - "Several studies have used CD157 in white blood cells with or without proaerolysin (fluorescein-labeled proaerolysin [FLAER])-based flow cytometry assays in the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH). " 05/01/2015 - "In the last few years, proaerolysin conjugated with fluorescein (FLAER) has become an important component of antibody panel used for the detection of paroxysmal nocturnal hemoglobinuria (PNH) clone. " 11/15/2006 - "Units of analysis in accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH." 07/15/2005 - "Accelerated telomere shortening in glycosylphosphatidylinositol (GPI)-negative compared with GPI-positive granulocytes from patients with paroxysmal nocturnal hemoglobinuria (PNH) detected by proaerolysin flow-FISH."
2.	Lower Urinary Tract Symptoms 04/01/2013 - "We conducted a safety and efficacy evaluation of intraprostatic injection of PRX302, a modified pore forming protein (proaerolysin) activated by prostate specific antigen, as a highly targeted, localized approach to treat lower urinary tract symptoms due to benign prostatic hyperplasia. "
3.	Prostatic Neoplasms (Prostate Cancer) 08/01/2007 - "Human prostate cancer cells were significantly more sensitive to recombinant modified proaerolysin in the presence of active prostate-specific antigen when compared with the absence of prostate-specific antigen or the presence of potent prostate-specific antigen inhibitors. "
4.	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 04/01/2013 - "We conducted a safety and efficacy evaluation of intraprostatic injection of PRX302, a modified pore forming protein (proaerolysin) activated by prostate specific antigen, as a highly targeted, localized approach to treat lower urinary tract symptoms due to benign prostatic hyperplasia. "
5.	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 08/01/2012 - "We used peripheral blood flow cytometry to identify glycosylphosphatidylinositol-anchor deficient blood cells, a proaerolysin-resistant colony forming cell assay to select glycosylphosphatidylinositol-anchor deficient progenitor cells, a novel T-lymphocyte enrichment culture assay with proaerolysin selection to expand glycosylphosphatidylinositol-anchor deficient T lymphocytes, and PIG-A gene sequencing assays to identify and analyze PIG-A mutations in patients with aplastic anemia and myelodysplastic syndromes. "

Related Drugs and Biologics

1.	Fluorescein (Funduscein)
2.	Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)
3.	Prostate-Specific Antigen (Semenogelase)
4.	Proteins (Proteins, Gene)
5.	PRX302